AN2 Therapeutics Phase 3 Trial Pause Impacts Stock
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
- Latest
- Trending
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
Financial institution Citi downgraded Everest Group's shares due to concerns over meeting margin targets. The downgrade prompted a reduced price ...
The highly-touted ERC-404 tokens on Ethereum have experienced a 29% drop in market capitalization, raising doubts about their viability and ...
Wall Street is eagerly waiting to see who emerges victorious in this Sunday's Super Bowl, as it is believed to ...
Discover the advantages and flaws of using artificial intelligence in the hiring process. Find out how AI can reduce bias, ...
Discover how Virtual Reality (VR) is revolutionizing gastrointestinal healthcare by modulating the mind-gut connection in this informative article. #VR #healthtech ...
Jim Cramer's changing stance on Bitcoin raises doubts amid ETF approval, with investors questioning the validity of his claims and ...
Artificial Intelligence models outperform clinical outcomes in ambulance care assessment, highlighting the potential to revolutionize patient assessment and decision-making in ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.